Development code · Small Molecule
MT-210
MT-210 is a development code for Roluperidone (MIN-101), developed by Minerva Neurosciences, Inc..
- Status
- Phase 3 for Schizophrenia
- Mechanism
- 5-HT2A Antagonist
- Developer
- Minerva Neurosciences, Inc.
Programs
- Roluperidone (MIN-101) for SchizophreniaPhase 3Active
Also known as
- MIN-101
- CYR-101
- roluperidone
- 359625-79-9